Study of ART0380 in Patients With Biologically Selected Solid Tumors

Summary

This interventional study will evaluate the efficacy and safety of ART0380 as monotherapy in patients whose tumors have a biology to predict for sensitivity to inhibition of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR).

Timeline

Start

2023-09-06

Primary completion

2024-11-15

Completion

2025-05-27

Drugs

Indications